Compare AstraZeneca plc (AZN) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Starbucks Corp — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Starbucks Corp trades at $108.48 (market cap $121.59B). The key difference: AstraZeneca plc is far larger — about 2× Starbucks Corp's market cap, and Starbucks Corp pays the higher dividend (2.33%). Which is the better fit depends on your goals.
| AZN | SBUX | |
|---|---|---|
Market Cap | $248.14B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $108.37 |
52-Week Low | $147.06 | $78.46 |
Enterprise Value | $275.41B | $140.42B |
Dividend Yield | 2.01% | 2.33% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
